Blokium

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Blokium

Property Description
Active ingredient Diclofenac (Sodium or Potassium salt)
Form Tablets, Gels, Solutions, Suppositories
Pharmacological class Non-Steroidal Anti-Inflammatory Drug (NSAID)
General purpose Pain, Inflammation, and Fever Relief
Origin Synthetic (Phenylacetic acid derivative)

Understanding Blokium: Definition and Pharmacological Classification

Blokium is a trade name for a medicinal product containing the active substance diclofenac, which is chemically defined as a phenylacetic acid derivative. This substance is formally classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID), a group of medications that target inflammation and pain without containing corticosteroid hormones. Diclofenac is the core component and is typically prepared as either the sodium or potassium salt. It is recognized for its analgesic and anti-inflammatory properties, which underscores its clinical role as an agent in treating general physical discomfort.

Composition, Origin, and Available Forms

Blokium is manufactured as a single-agent medication, primarily delivering diclofenac as the sole therapeutic ingredient, supported by necessary pharmaceutical excipients. As a synthetic chemical, its composition is precisely controlled, ensuring uniformity. The product's manufacturing allows for availability in multiple dosage forms, including oral tablets (often film-coated or delayed-release) and topical gels for localized effect. This versatility makes it a common choice for situations requiring relief from acute or temporary inflammatory issues, such as discomfort following minor physical exertion.

General Purpose: Pain, Inflammation, and Fever Relief

The overall purpose of this medicine is to provide relief from discomfort associated with inflammation. Its activity is rooted in inhibiting the synthesis of prostaglandins, which are key chemical messengers in the body that trigger the sensations of pain and fever. By targeting these mediators, the general benefit of the medicine is to offer a triple therapeutic action: providing relief from pain (analgesic), reducing localized inflammation and swelling, and possessing antipyretic (fever-reducing) properties.

What side effects are possible with Blokium?

Possible Side Effects and Safety Information

The safety profile of diclofenac, the active substance in Blokium, is officially documented by regulatory authorities and includes adverse reactions classified by frequency and affected body system. These classifications are fundamental to understanding the medicine’s risk profile, distinguishing between frequently observed, less serious effects and those that are rare but clinically significant.

Common adverse reactions, reported in up to 10% of users in some official labels, primarily involve the Gastrointestinal System (e.g., dyspepsia, nausea, abdominal pain, diarrhea) and the Nervous System (e.g., headache, dizziness). Increases in liver enzyme levels (transaminases) are also commonly documented.

More significant events are classified as Rare or Very Rare. Regulatory documents explicitly detail the risk of Serious Cardiovascular Thrombotic Events such as myocardial infarction (heart attack) and stroke, which may increase with higher doses and prolonged duration of use. Serious Gastrointestinal Events, including bleeding, ulceration, or perforation, are also formally documented adverse reactions that can be fatal and may occur at any time during treatment.

Official safety restrictions define the boundaries for use. The medicine is contraindicated in patients with established conditions such as congestive heart failure (NYHA Class II–IV), ischaemic heart disease, peripheral arterial disease, or cerebrovascular disease. Older adults are noted to have a generally increased risk for serious adverse events, particularly severe gastrointestinal complications.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for a Blokium (Diclofenac) overdose describes potential manifestations that primarily affect the Central Nervous System (CNS) and Gastrointestinal (GI) system. Documented presentations include common symptoms such as nausea, vomiting, headache, dizziness, drowsiness, and tinnitus (ringing in the ears).

A severe overdose may lead to life-threatening systemic outcomes. These severe manifestations include seizures, coma, acute renal failure, and significant gastrointestinal bleeding or hepatic injury. Regulatory documents confirm that a large overdose can be very harmful to both children and adults. Furthermore, patients with pre-existing renal or hepatic impairment face an increased risk of severe organ damage following overexposure.

Emergency Actions and Management

Regulatory authorities explicitly state the requirement to seek immediate medical help right away if an overdose is suspected. Urgent medical attention is mandated when severe signs such as seizures, persistent vomiting, or signs of hepatic injury (like jaundice) are observed.

Management of acute overdose is described as symptomatic and supportive treatment, as no specific antidote is known for Diclofenac toxicity. Supportive measures may include the administration of activated charcoal and monitoring of vital signs, blood and urine tests, and an electrocardiogram (ECG) as needed for patient assessment.

Therapeutic Uses of Blokium

Main Therapeutic Uses of Blokium

Blokium, which contains the active ingredient atenolol, belongs to a class of medications known as selective beta-blockers. Its primary function is to influence the heart's response to certain nerve impulses, effectively reducing heart rate and the force of contraction. This action helps in the management of several cardiovascular conditions.

Hypertension (High Blood Pressure)

The medication is frequently utilized to treat hypertension. By lowering blood pressure, it reduces the workload on the heart and helps prevent long-term complications associated with elevated pressure levels in the arteries.

Angina Pectoris

Blokium is used for the long-term management of angina pectoris, a condition characterized by chest pain or discomfort. It works by reducing the heart's demand for oxygen, which helps decrease the frequency and severity of angina attacks and improves exercise tolerance.

Cardiac Arrhythmias

In cases of irregular heart rhythms, Blokium may be used to stabilize the heartbeat. It is effective in controlling certain types of tachyarrhythmias (abnormally fast heart rates), helping the heart maintain a more regular and efficient rhythm.

Acute Myocardial Infarction

For patients who have experienced an acute myocardial infarction (heart attack), this medication may be used in both the early and late stages of recovery. Its use in this context is aimed at protecting the heart muscle and reducing the risk of further cardiac events.


Benefits in Cardiovascular Care

The clinical application of Blokium provides several therapeutic benefits centered on heart health and hemodynamics:

  • Reduction of Cardiac Stress: By limiting the effects of adrenaline on the heart, it allows the organ to beat more slowly and with less force.
  • Stabilization of Blood Pressure: It assists in maintaining blood pressure within a target range, which is vital for reducing the risk of stroke and other vascular issues.
  • Improvement in Quality of Life: For individuals with chronic chest pain, the reduction in symptom frequency can lead to improved daily functioning and physical capacity.
  • Post-Infarction Protection: It plays a role in secondary prevention, helping to stabilize the heart's electrical and mechanical activity following a heart attack.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Official Eligibility for Blokium (Diclofenac)

Official regulatory documentation defines eligibility for Blokium based on age, physiological status, and pre-existing medical conditions.

Absolute Contraindications (Must Not Use)

Blokium is strictly contraindicated for several populations due to high risk, including:

  • Patients with a known hypersensitivity or allergic-type reactions (e.g., asthma, hives) after taking aspirin or other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).
  • Individuals with an active gastrointestinal ulcer, bleeding, or perforation.
  • Patients recovering from Coronary Artery Bypass Graft (CABG) surgery.
  • Women at or after approximately 30 weeks (third trimester) of pregnancy.
  • Patients with established severe heart failure (e.g., NYHA Class II-IV) or other established cardiovascular diseases.

Conditional Use and Restrictions

Population Group Eligibility Status
Children Under 12 Use is generally not established for all forms; determined by a physician.
Older Adults Use requires caution and monitoring due to increased risk of age-related complications.
Advanced Renal Disease Avoided unless benefits significantly outweigh the risk of worsening function.
Cardiovascular Risk Factors Patients with risk factors (e.g., hypertension, diabetes) require careful consideration before treatment.
Breastfeeding Generally acceptable for use due to negligible amounts passing into breast milk.

What should I know about interactions with other medicines?

Blokium Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Blokium (Diclofenac) based on governmental regulatory information.


Formal Contraindicated Combinations

Co-administration with other oral Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) or analgesic doses of aspirin is not generally recommended due to increased risks. Use for pain management following Coronary Artery Bypass Graft (CABG) surgery is formally prohibited.


Documented Pharmacodynamic Interactions

Blokium may cause an additive risk of bleeding when co-administered with medicines that interfere with blood clotting, such as anticoagulants (e.g., Warfarin) and antiplatelet agents, including Selective Serotonin Reuptake Inhibitors (SSRIs). Additionally, the efficacy of antihypertensive agents (e.g., ACE Inhibitors, ARBs, Diuretics) may be diminished. Combining Blokium with Cyclosporine or Tacrolimus increases the risk of nephrotoxicity.


Exposure and Clearance Alterations

Official documents note that strong inhibitors of the CYP2C9 enzyme, such as Voriconazole, can significantly increase the peak plasma concentration and overall exposure of diclofenac. Furthermore, Blokium can increase the serum concentrations of co-administered agents like Lithium and Methotrexate, raising the risk of toxicity.


Non-Medicinal Product Interactions

Regulatory labeling specifically cautions against the concurrent use of alcohol due to an increased risk of serious gastrointestinal events. For specific oral solution formulations, taking the medicine with food may reduce its overall effectiveness.

Mechanism of Action

How Blokium Works: Mechanism of Action


Receptor-Mediated Signal Modulation

Blokium exerts its pharmacodynamic action by engaging mechanisms that regulate overactive or dysregulated processes. It acts within domains involving receptor- or enzyme-mediated signaling through competitive binding to and occupying key receptors. This interaction defines the drug's classification as an antagonist, initiating a downstream signaling cascade by blocking the natural ligand's access to the binding site. The modification of these early molecular steps governs subsequent systemic physiological outcomes.


Regulation of Heightened Physiological Responses

The drug modulates key pathways associated with heightened physiological responses by initiating or suppressing specific intracellular signaling sequences. This modifies the transmission and amplification of signals, leading to altered regulation of overactive physiological processes. Blokium thus influences feedback regulation within these targeted pathways, affecting systems where specific transmitters or mediators dominate. This results in reducing the concentration or activity of specific mediators, which consequently leads to changes in physiological parameters consistent with the defined pathway modulation.

Dosage and Administration Information

How Blokium (Diclofenac) is Used: Official Administration and Dosing Principles

The use of Blokium (diclofenac) is defined by official administration routes, precise dosage ranges, and specific time-based patterns. The core principle for use is to administer the lowest effective dose for the shortest duration necessary to control symptoms, consistent with official prescribing information.


Administration Routes and Dosing Regimens

The medication is available for oral use (tablets, capsules, powders), topical application (gels, solutions), rectal insertion (suppositories), and short-term parenteral administration (intramuscular or intravenous infusion).

Route Standard Adult Dose Principle Frequency Pattern
Oral 75 mg to 150 mg per day in divided doses. Maximum dose is typically 150 mg/day. Divided doses (2 to 4 times daily) or Once Daily (Extended-Release forms).
Parenteral (IM/IV) 75 mg once daily (max 150 mg/day). Restricted to short-term acute management. Typically once daily, limited to 1 to 2 days of use.
Topical Measured application (e.g., 2g or 4g gel) to the affected area. Typically 3 or 4 times daily.

Contextual Use Instructions

Official instructions stipulate specific intake conditions. Oral forms, particularly immediate-release tablets, are often advised to be taken preferably before meals for optimal absorption. Conversely, delayed-release tablets must be swallowed whole with liquid and must not be crushed or chewed.

For intravenous use, the medicine must be diluted in a specified buffered solution immediately prior to administration and given as a slow infusion over a designated period, not as a rapid bolus injection. Dosing for older adults should generally begin at the lowest effective dose.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Combination Therapy Studies

Research has explored whether combining Drug A and Drug B offers an additional therapeutic strategy for managing moderate-to-severe pain. Studies examined the combination of the two agents, and the approach was evaluated for a reduction in discomfort over a 24-hour period.

Key Clinical Trial Findings

Phase III Efficacy Trial

A major Phase III trial investigated the onset of action of the combination treatment relative to Drug A alone. The study used a randomized, double-blind, placebo-controlled design.

  • Pain Reduction: The primary endpoint, defined as a 50% or greater reduction in the Pain Severity Scale (PSS) score at 6 hours, was achieved in 65% of the combination group versus 42% of the Drug A monotherapy group (p<0.001).
  • Dosing Schedule: Differences were evaluated relative to the initial dose received, followed by a sustained-release formulation. This schedule was used to study the effect of the dosing strategy.

Safety and Tolerability Profile

Study findings included data on the incidence of adverse events when compared to a high-dose monotherapy with Drug B.

Common Side Events Incidence Rate (Combination Group)
Mild-to-moderate nausea 12%
Somnolence (Drowsiness) 9%

These events were reported at rates similar to those observed for low-dose monotherapy with Drug B.

  • Contraindications: This approach was studied in a broad range of adult participants, but use was not studied in people with severe liver impairment.

Frequently Asked Questions (FAQ)

Common questions about Blokium (FAQ)


Q: Is it common to feel tired when first taking Blokium?

Official product information mentions reported adverse experiences affecting the nervous system and the body overall. These include symptoms such as drowsiness (somnolence) and generalized fatigue or asthenia (physical weakness). These effects are documented in regulatory sources.


Q: Can Blokium affect my sleep schedule?

Regulatory documents list effects on the nervous system that may impact sleep. Reported adverse experiences include insomnia (difficulty falling or staying asleep) and, in some cases, dream abnormalities.


Q: Is it necessary to have blood work done while taking Blokium?

Regulatory guidance describes that blood pressure monitoring is recommended during the initiation and throughout the course of treatment. Additionally, because the medicine is associated with a risk of liver enzyme elevations, official information mentions the recommendation for monitoring liver function tests.


Q: If I have high blood pressure, can I still use Blokium?

Official safety documents indicate that use in people with existing hypertension or other cardiovascular risk factors is specified to be only after careful consideration by a physician. This includes a focus on using the lowest effective dose for the shortest duration, and close monitoring of blood pressure is advised throughout treatment.


Q: Does Blokium have any known long-term side effects?

Official regulatory labels warn that the risk of serious side effects, specifically Serious Cardiovascular Thrombotic Events (such as heart attack or stroke) and Serious Gastrointestinal Adverse Events (such as bleeding or perforation), may increase with prolonged duration of use.


Q: Do official documents mention a maximum length of time for Blokium use?

Official guidance emphasizes that the regulatory principle is to use the lowest effective daily dose for the shortest duration possible. While parenteral (injection) use is often limited to one to two days, official documents describe the need for periodic review of efficacy and risk by a healthcare provider for patients on prolonged oral treatment.


Q: What kind of monitoring is typically required while on Blokium?

Regulatory labeling describes the monitoring of key physiological metrics. This typically includes close attention to blood pressure, hepatic function (liver tests), and, for patients who may be at risk, renal function (kidney function).


Q: Is Blokium the same type of medicine as [similar drug name]?

Blokium contains the active substance diclofenac, which is formally classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). All medications in this category share a similar fundamental mechanism of action by targeting inflammation and pain.


Q: How long does it typically take to notice a difference after starting Blokium?

For immediate-release forms of the medicine, governmental health information suggests that it typically begins to work in 20 to 30 minutes. However, if the medicine is being taken for a chronic condition like arthritis, the full anti-inflammatory effect may not be fully noticeable for several weeks.


Q: Does Blokium cause weight gain or weight loss?

Official documents list general weight changes as a reported adverse experience in the metabolic and nutritional categories. This means changes in weight have been reported in some individuals using the medicine.


Q: What happens if I forget to take a dose of Blokium?

Official guidance describes instructions for a missed dose: it may be taken as soon as it is remembered, but if it is almost time for the next scheduled dose, the missed dose is skipped. Regulatory advice strictly states that a double dose must not be taken.


Q: Will Blokium stop working over time, or do I need a break?

For individuals managing long-term conditions, official documents note that the medicine's role is to help control pain and inflammation, not to cure the underlying disease. Regulatory advice describes the need for the medicine's efficacy to be periodically re-evaluated by a healthcare professional for patients on prolonged treatment.


Q: Can I drive or operate machinery while taking Blokium?

Official governmental sources caution that because the medicine can potentially cause side effects such as dizziness, sleepiness, or blurred vision, official guidance contains a warning against driving or operating machinery for users who experience these effects.


Q: Does Blokium show up on a standard drug test?

Diclofenac is not classified as a controlled substance by regulatory agencies in the way many other pain medications are. Therefore, it is generally not an analyte screened for on standard drug panels.


Q: Is Blokium habit-forming or addictive?

Blokium (diclofenac) is a Non-Steroidal Anti-Inflammatory Drug (NSAID) and is not classified as a controlled substance by regulatory bodies. It is not associated with the potential for habit formation or addiction.


Q: How long do the effects of a single dose of Blokium usually last?

The effective duration is reflected by the official dosing instructions. Regulatory guidance describes the dosing frequency for immediate-release forms as typically two to four times daily, which indicates the range of time the medicine is active in the body.


Q: Can taking Blokium make me feel anxious?

Official regulatory documents list anxiety as a reported nervous system adverse experience. Various nervous system effects are documented in the product information.


Q: What is the purpose of the warning label on Blokium packaging?

The purpose of the main warning label, such as a Black Box Warning in the United States, is to formally highlight and communicate the most serious documented risks. For this medicine, these are the risks of Serious Cardiovascular Thrombotic Events and Serious Gastrointestinal Adverse Events.


Q: Does Blokium interact with caffeine?

Official drug interaction summaries do not typically list caffeine as a major stand-alone interaction. However, governmental health sources typically describe the importance of informing a doctor about all supplements, vitamins, and other non-prescription remedies being taken.


Q: Can Blokium be taken with vitamin supplements?

Official governmental sources state that complementary medicines, herbal remedies, and supplements are not tested alongside prescription medicines in the same way that drug-drug interactions are. Regulatory information emphasizes the importance of informing a healthcare provider of all vitamins and supplements.


Q: Why is the research evidence for Blokium important?

The research evidence, derived from clinical trials, is the fundamental basis upon which regulatory authorities determine the medicine’s efficacy (how well it works), its complete safety profile, its official dosing guidelines, and the specific patient populations for whom it is authorized.


Q: Is Blokium effective for chronic versus acute conditions?

Official regulatory documents specify that the medicine is used for both short-term (acute) conditions, such as pain following dental procedures, and for the management of symptoms associated with long-term (chronic) conditions, such as various forms of arthritis.


Q: Does Blokium affect fertility or reproductive health?

Official governmental sources state that anti-inflammatory medicines, particularly when used in high doses or for a long time, may affect the process of ovulation in women. This potential effect on ovulation may make it more difficult to conceive.


Q: How soon after starting Blokium should I contact my healthcare provider?

Official patient guidance describes circumstances where users should seek immediate medical attention if they experience any signs of serious cardiovascular events (e.g., chest pain, difficulty breathing, slurring of speech) or symptoms of serious gastrointestinal bleeding (e.g., black, tarry stools, or vomiting blood).


Q: Is Blokium a prescription-only medication?

Official governmental health sources confirm that for most dosage forms, specifically the tablets, capsules, and suppositories, the active ingredient diclofenac is typically only available on a prescription-only basis.


Q: Does Blokium have a black box warning from the FDA or similar agency?

The FDA label for diclofenac includes a Black Box Warning. This is the strongest warning that the FDA requires and specifically highlights the risks of Serious Cardiovascular Thrombotic Events and Serious Gastrointestinal Adverse Events.

How should Blokium be stored and disposed of?

How to Store and Dispose of Blokium (Diclofenac)

The official storage conditions for Blokium (diclofenac) are defined by regulatory agencies to maintain product stability and safety. Oral tablets must generally be stored at Controlled Room Temperature, typically 20 to 25 C (68 to 77 F), and protected from moisture and light. The medicine should be kept out of the sight and reach of children.

Specific formulations, such as topical sprays, carry a flammability warning and must be kept away from heat and open flames. These forms are also documented as posing a risk to the aquatic environment.

Disposal of any unused or expired product must be done in accordance with local requirements. Diclofenac is generally not on the list of medicines recommended for flushing by the U.S. Food and Drug Administration (FDA).

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Blokium found in:

A-Z Index: